SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN

被引：0

作者：

Ramirez de Arellano, A. ^{[1
]}

Morales, C. ^{[2
]}

De Luis, D. ^{[3
]}

Ferrario, M. G. ^{[4
]}

Lizan, L. ^{[4
]}

机构：

[1] Novo Nordisk Pharma SA, Madrid, Spain

[2] Hosp Virgen de la Macarena, Seville, Spain

[3] Hosp Rio Hortega, Valladolid, Spain

[4] Outcomes10, Castellon de La Plana, Spain

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB63

引用

页码：A343 / A343

页数：1

共 50 条

[41] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334
[42] Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: Modeling analysis using an observational study
Minshall, M. E.
Tunis, S. L.
Conner, C.
McCormick, J., I
Kapor, J.
Groleau, D.
[J]. VALUE IN HEALTH, 2008, 11 (03) : A224 - A224
[43] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Simon, A. C. R.
Swinnen, S. G.
Holleman, F.
Hoekstra, J. B. L.
DeVries, J. H.
[J]. DIABETOLOGIA, 2011, 54 : S420 - S421
[44] Comparative Effectiveness of Long-Acting Insulin Analogs and Neutral Protamine Hagedorn (nph) Insulin for the Reduction of Major Adverse Cardiovascular Events Among Patients With Type 2 Diabetes
Brunetti, Vanessa C. C.
Yu, Oriana H.
Platt, Robert W.
Filion, Kristian B.
[J]. CIRCULATION, 2021, 144
[45] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
[J]. DIABETES, 2005, 54 : A609 - A609
[46] COST-EFFECTIVENESS OF INSULIN DETEMIR IN T2DM PATIENTS POORLY CONTROLLED WITH NPH INSULIN IN POLAND
Kaczor, M. P.
Pawlik, D.
Wojcik, R.
Jurkiewicz, B.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
[47] EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING
Fan, C. S.
Zhong, J.
Sun, F.
Liu, F.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A162 - A163
[48] THE UTILISATION AND SWITCHING RATES OF NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN AND LONG-ACTING INSULIN ANALOGS IN PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM
Brunetti, V. C.
Yu, O. H. Y.
Platt, R. W.
Filion, K. B.
[J]. VALUE IN HEALTH, 2020, 23 : S512 - S512
[49] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, Sanne G.
Simon, Airin C. R.
Holleman, Frits
Hoekstra, Joost B.
DeVries, J. Hans
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (07):
[50] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK
McEwan, Phil
Poole, Chris D.
Tetlow, Tony
Holmes, Paul
Currie, Craig J.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S7 - S19

← 1 2 3 4 5 →